(Q47375187)

15 January 2018

title

Is there really a yin and yang to VEGF-targeted therapies? (English)

1 reference

15 January 2018

2

David A Reardon

1 reference

15 January 2018

Lee M Ellis

1

1 reference

15 January 2018

publication date

13 July 2010

1 reference

15 January 2018

Lancet Oncology Commission

published in

1 reference

15 January 2018

volume

11

1 reference

15 January 2018

issue

9

1 reference

15 January 2018

page(s)

809-811

1 reference

15 January 2018

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970161-3

7 January 2021

HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970161-3

7 January 2021

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970161-3

7 January 2021

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970161-3

7 January 2021

Rapid vascular regrowth in tumors after reversal of VEGF inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970161-3

7 January 2021

Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970161-3

7 January 2021

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970161-3

7 January 2021

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970161-3

7 January 2021

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970161-3

7 January 2021

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970161-3

7 January 2021

10.1016/S1470-2045(10)70161-3

Identifiers

DOI

1 reference

15 January 2018

1 reference

15 January 2018